MediWound to Host Virtual KOL Event on EscharEx® Phase III VALUE Study and Commercial Opportunity on December 2, 2026GlobeNewsWire • Monday
MediWound Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/12/26
MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary SharesGlobeNewsWire • 11/05/26
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®GlobeNewsWire • 09/22/26
Independent DSMB Recommends MediWound's EscharEx® Phase III VALUE Study Continue Without ModificationGlobeNewsWire • 09/14/26
MediWound to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire • 09/02/26
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/13/26
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/27/26
Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound DebridementGlobeNewsWire • 04/13/26
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 MillionGlobeNewsWire • 04/02/26